靶向放射性核素治疗：向精准癌症治疗的演进
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
作者信息
Jadvar Hossein
机构信息
1 Department of Radiology, Division of Nuclear Medicine, Keck School of Medicine, University of Southern California, 2250 Alcazar St, CSC Ste 102, Los Angeles, CA 90033.
出版信息
AJR Am J Roentgenol. 2017 Aug;209(2):277-288. doi: 10.2214/AJR.17.18264. Epub 2017 May 2.
Abstract
OBJECTIVE
This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field.
CONCLUSION
TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of "see and treat" within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.
摘要
目的
本文综述了针对恶性肝病变、骨转移、神经内分泌肿瘤和去势抵抗性转移性前列腺癌的靶向放射性核素治疗（TRT）方法的最新进展，并讨论了该领域的挑战与机遇。
结论
自近75年前首次进行放射性碘甲状腺治疗以来，TRT就已被应用。对癌症复杂基础生物学的理解取得进展、放射化学科学的进步、包括治疗诊断学框架内“可视即治疗”概念在内的多模态成像技术，以及精准医学理念的广泛接受，都促使TRT再度兴起。
相似文献
1
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
AJR Am J Roentgenol. 2017 Aug;209(2):277-288. doi: 10.2214/AJR.17.18264. Epub 2017 May 2.
2
[Radionuclide therapy for cancer--what's new?].
Duodecim. 2012;128(21):2209-16.
3
Radionuclide therapy beyond radioiodine.
Wien Med Wochenschr. 2012 Oct;162(19-20):430-9. doi: 10.1007/s10354-012-0128-6. Epub 2012 Jul 20.
4
[Nuclear medicine in oncotherapy].
Magy Onkol. 2015 Sep;59(3):193-7. Epub 2015 Apr 11.
5
Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Nanotheranostics. 2022 Jan 1;6(1):103-117. doi: 10.7150/ntno.64141. eCollection 2022.
6
Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy.
Ann Nucl Med. 2007 Jul;21(5):307-10. doi: 10.1007/s12149-007-0020-4. Epub 2007 Jul 25.
7
Radionuclide Therapies: An Overview of Applications.
Radiol Technol. 2021 Jul;92(6):595-614.
8
Radionuclide Therapies in Molecular Imaging and Precision Medicine.
PET Clin. 2017 Jan;12(1):93-103. doi: 10.1016/j.cpet.2016.08.006. Epub 2016 Sep 19.
9
Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
Nuklearmedizin. 2010;49(1):N2-3.
10
Recent advances in nuclear medicine in endocrine oncology.
Curr Opin Oncol. 2017 Jan;29(1):1-6. doi: 10.1097/CCO.0000000000000338.
引用本文的文献
1
Framework to calculate Ac, Lu, and Tb radiation dose and biological effect in metastatic castration-resistant prostate cancer treatment.
Med Phys. 2025 Aug;52(8):e18035. doi: 10.1002/mp.18035.
2
Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review.
Pharmaceuticals (Basel). 2025 Apr 2;18(4):519. doi: 10.3390/ph18040519.
3
Advancements in delivery systems for dietary polyphenols in enhancing radioprotection effects: challenges and opportunities.
NPJ Sci Food. 2025 Apr 14;9(1):51. doi: 10.1038/s41538-025-00419-6.
4
177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors.
Mol Cancer Ther. 2025 Jun 4;24(6):907-919. doi: 10.1158/1535-7163.MCT-24-0254.
5
Improvement of End-of-Synthesis Radiochemical Purity of Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization.
Pharmaceutics. 2024 Nov 30;16(12):1535. doi: 10.3390/pharmaceutics16121535.
6
Exploring key features of selectivity in somatostatin receptors through molecular dynamics simulations.
Comput Struct Biotechnol J. 2024 Mar 18;23:1311-1319. doi: 10.1016/j.csbj.2024.03.005. eCollection 2024 Dec.
7
Calculation of alpha particle single-event spectra using a neural network.
Front Oncol. 2024 Oct 2;14:1394671. doi: 10.3389/fonc.2024.1394671. eCollection 2024.
8
Nanoscale Radiotheranostics for Cancer Treatment: From Bench to Bedside.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Sep-Oct;16(5):e2006. doi: 10.1002/wnan.2006.
9
The application of radionuclide therapy for breast cancer.
Front Nucl Med. 2024 Jan 10;3:1323514. doi: 10.3389/fnume.2023.1323514. eCollection 2023.
10
Enhancement of gold-curcumin nanoparticle mediated radiation response for improved therapy in cervical cancer: a computational approach and predictive pathway analysis.
Discov Nano. 2024 Sep 18;19(1):153. doi: 10.1186/s11671-024-04104-7.
本文引用的文献
1
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.
2
Radionuclide Therapy for Neuroendocrine Tumors.
Curr Oncol Rep. 2017 Feb;19(2):9. doi: 10.1007/s11912-017-0567-8.
3
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1185-1193. doi: 10.1007/s00259-017-3646-z. Epub 2017 Feb 14.
4
Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
J Gastroenterol Hepatol. 2017 Sep;32(9):1617-1623. doi: 10.1111/jgh.13752.
5
Differences in Radiation Activity Between Glass and Resin 90Y Microspheres in Treating Unresectable Hepatic Cancer.
Health Phys. 2017 Mar;112(3):300-304. doi: 10.1097/HP.0000000000000631.
6
Sc-PSMA-617 for radiotheragnostics in tandem with Lu-PSMA-617-preclinical investigations in comparison with Ga-PSMA-11 and Ga-PSMA-617.
EJNMMI Res. 2017 Dec;7(1):9. doi: 10.1186/s13550-017-0257-4. Epub 2017 Jan 19.
7
Resin Versus Glass Microspheres for Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry.
J Nucl Med. 2017 Aug;58(8):1334-1340. doi: 10.2967/jnumed.116.184713. Epub 2017 Jan 12.
8
Assessing Intra-arterial Complications of Planning and Treatment Angiograms for Y-90 Radioembolization.
Cardiovasc Intervent Radiol. 2017 May;40(5):704-711. doi: 10.1007/s00270-016-1555-3. Epub 2017 Jan 11.
9
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
10
Personnel dose reduction in Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward.
Br J Radiol. 2017 Mar;90(1071):20160591. doi: 10.1259/bjr.20160591. Epub 2016 Dec 20.
Zotero 插件